OptimizeRx Analyst Price Targets - Benzinga

OptimizeRx Corp

OPRXNASDAQ

Trade with Public

Trade with Public

$8.72

0.151.75%

마지막 업데이트: Oct 5, 4:00 PM

$8.72

0.151.75%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

OptimizeRx Analyst Price Targets - Benzinga

OptimizeRx Analyst Price Targets

Wall Street analyst price targets and consensus rating for OptimizeRx (OPRX).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

2S.Buy

5Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$12Upside to Avg. PT+38.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	B. Riley Securities	Josh Nichols	PT Raise	Buy	$10→$11
Aug 14, 2026	Citizens	Constantine Davides	PT Raise	Market Outperform	$9→$11
May 13, 2026	Lake Street	Eric Martinuzzi	PT Cut	Buy	$20→$11
May 13, 2026	B. Riley Securities	Anderson Schock	PT Cut	Buy	$11→$10
May 13, 2026	Stephens & Co.	Jeff Garro	PT Cut	Equal-Weight	$10→$7
May 13, 2026	Stifel	David Grossman	PT Cut	Buy	$17→$14
Mar 6, 2026	Lake Street	Eric Martinuzzi	PT Cut	Buy	$24→$20
Mar 6, 2026	Roth Capital	Richard Baldry	PT Cut	Buy	$32→$18
Mar 6, 2026	B. Riley Securities	Anderson Schock	PT Cut	Buy	$28→$11
Mar 6, 2026	Stephens & Co.	Jeff Garro	PT Cut	Equal-Weight	$17→$10
Mar 6, 2026	Stifel	David Grossman	PT Cut	Buy	$21→$17
Nov 17, 2025	Stephens & Co.	Jeff Garro	PT Cut	Equal-Weight	$20→$17
Nov 7, 2025	Citizens	Constantine Davides	PT Raise	Market Outperform	$23→$24
Oct 10, 2025	JMP Securities	Constantine Davides	PT Raise	Market Outperform	$20→$23
Aug 11, 2025	JMP Securities	Constantine Davides	PT Raise	Market Outperform	$14→$20
Aug 8, 2025	Stifel	David Grossman	PT Raise	Buy	$16→$18
Jun 9, 2025	Stifel	David Grossman	PT Raise	Buy	$13→$16
May 13, 2025	Stifel	David Grossman	PT Raise	Buy	$8→$13
May 13, 2025	JMP Securities	Constantine Davides	PT Raise	Market Outperform	$11→$14
Feb 6, 2025	JMP Securities	Constantine Davides	Maintained	Market Outperform	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11

B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11

Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11

Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $20 to $11.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10

B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.

Benzinga Newsdesk